As the CEO of IHMA Europe Sàrl, Stephen Hawser plays a pivotal role in advancing the field of anti-infective therapy development. Based in the picturesque Monthey, Switzerland, near the serene shores of Lake Geneva, Stephen leads a team dedicated to providing cutting-edge laboratory services that...
As the CEO of IHMA Europe Sàrl, Stephen Hawser plays a pivotal role in advancing the field of anti-infective therapy development. Based in the picturesque Monthey, Switzerland, near the serene shores of Lake Geneva, Stephen leads a team dedicated to providing cutting-edge laboratory services that span the entire lifecycle of drug development. Since the establishment of IHMA Europe in February 2009, the organization has emerged as a premier provider of central, reference, and clinical research laboratory services, catering to the needs of biopharmaceutical companies worldwide.
Under Stephen's leadership, IHMA has focused on supporting innovative projects that address critical challenges in infectious diseases. His expertise in molecular biology and biotechnology, combined with a deep understanding of the pharmaceutical industry, enables IHMA to offer comprehensive consulting services that enhance the efficacy of drug development processes. Stephen's commitment to advancing in vitro diagnostics (IVD) and tackling biofilm-related issues has positioned IHMA as a key player in the fight against antibiotic resistance.
Stephen's strategic vision encompasses not only the operational excellence of IHMA but also the cultivation of partnerships with leading research institutions and biopharmaceutical companies. By fostering collaboration and leveraging state-of-the-art laboratory capabilities, he ensures that IHMA remains at the forefront of clinical trials and drug commercialization efforts. With a focus on delivering high-quality results and innovative solutions, Stephen Hawser continues to drive IHMA Europe Sàrl's mission of improving patient outcomes through effective anti-infective therapies.
